Germany in Vitro Diagnostics Investment Opportunities

Analysis and Forecasts to 2015

Product Code GMD08319
Publication Date April 2009
Publisher Global Markets Direct
Product Type Report
Pages 155
ISBN Number not applicable
Change currency
PDF £1,580.00 €1,903 $2,498 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Germany in Vitro Diagnostics Investment Opportunities

Analysis and Forecasts to 2015

This report is an essential source for in-depth information and data relating to the GermanyIn vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in Germany

Scope

  • The report provides in vitro diagnostics information broken down into detailed categories and segments in Germany.
  • Total revenues, end users
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the in vitro diagnostics devices market in Germany.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets Covered in This Report
    • 3.1 In Vitro Diagnostics
    • 3.2 Clinical Chemistry Test Reagents
      • 3.2.1 Laboratory Reagents
      • 3.2.2 Clinical Chemistry Calibrators and Controls
      • 3.2.3 Clinical Chemistry Rapid Tests
    • 3.3 Immunochemistry Test Reagents
      • 3.3.1 Disease Specific Markers
        • 3.3.1.1 Tumor Markers
        • 3.3.1.2 Cardiac Markers
      • 3.3.2 Disease Specific Test Reagents
        • 3.3.2.1 Auto-Immune Disease
        • 3.3.2.2 Rheumatoid Disease
        • 3.3.2.3 Anemia/ Vitamins
        • 3.3.2.4 Allergy
      • 3.3.3 Drug Related Testing Reagents
        • 3.3.3.1 Therapeutic Drugs
        • 3.3.3.2 Drug of Abuse and Toxicology
      • 3.3.4 Hormone Related Testing Reagents
        • 3.3.4.1 Specific Proteins
        • 3.3.4.2 Fertility and Pregnancy
        • 3.3.4.3 Individual/Specified hormones
        • 3.3.4.4 Specific Organ Function
      • 3.3.5 Immunochemistry Calibrators and Controls
      • 3.3.6 Immunochemistry Rapid Tests
    • 3.4 Blood Test Reagents
      • 3.4.1 Hematology Test Reagents
        • 3.4.1.1 Hematology
        • 3.4.1.2 Immunohaematology
        • 3.4.1.3 Hematology Calibrators and Controls
        • 3.4.1.4 Immunohaematology Controls
      • 3.4.2 Hemostasis Test Reagents
        • 3.4.2.1 Hemostasis
        • 3.4.2.2 Hemostasis Calibrators and Controls
        • 3.4.2.3 Hemostasis Rapid Tests
      • 3.4.3 Tissue Typing Reagents
      • 3.4.4 Monoclonal Antibodies
      • 3.4.5 Cytokines and Immunomodulators
      • 3.4.6 Histology and Cytology Reagents
    • 3.5 Microbiology Test Reagents
      • 3.5.1 Bacteriology Test Reagents
        • 3.5.1.1 Bacteriology Culture
        • 3.5.1.2 Blood Culture
        • 3.5.1.3 Bacteriology Identification and Susceptibility
      • 3.5.2 Microbiology Calibrators and Controls
      • 3.5.3 Microbiology Rapid Tests
    • 3.6 Infectious Immunology Test Reagents
      • 3.6.1 Bacteriology
      • 3.6.2 Virology
        • 3.6.2.1 Hepatitis Viruses
        • 3.6.2.2 Retroviruses
      • 3.6.3 Parasitology
      • 3.6.4 Infectious Immunology Calibrators and Controls
      • 3.6.5 Infectious Immunology Rapid Tests
    • 3.7 Genetic Test Reagents
    • 3.8 Self Testing
    • 3.9 Instruments
  • 4 Healthcare Sector Review
    • 4.1 Healthcare Sector
    • 4.2 Healthcare Expenditure
    • 4.3 Healthcare Infrastructure
      • 4.3.1 Healthcare Personnel Data
      • 4.3.2 Healthcare Facilities Data
    • 4.4 Healthcare Policy
  • 5 Regulation System
    • 5.1 Regulation System
    • 5.2 Medical Equipment Approval Process
      • 5.2.1 Classification of Medical Devices
    • 5.3 Conformity Assessment Process
      • 5.3.1 Class I devices
      • 5.3.2 Class IIa devices
      • 5.3.3 Class IIb devices
      • 5.3.4 Class III devices
    • 5.4 Post Market Surveillance
  • 6 Pricing and Reimbursement
    • 6.1 SHI
      • 6.1.1 Private Health Insurance
      • 6.1.2 Diagnosis Related Groups (DRG)
  • 7 Distribution Structure
  • 8 In Vitro Diagnostics In Germany
    • 8.1 In Vitro Diagnostics, Germany, Overall Revenue ($ mn), 2000-2015
    • 8.2 In Vitro Diagnostics, Germany, Company Share (2006-2007)
  • 9 Blood Test Reagents In Germany
    • 9.1 Blood Test Reagents Overall Revenue (2000-2015)
      • 9.1.1 Haematology Test Reagents Revenue (2000-2015)
      • 9.1.2 Hemostasis Test Reagents Revenue (2000-2015)
    • 9.2 Blood Test Reagents Distribution Share (2007-2008)
    • 9.3 Blood Test Reagents, Germany, Company Share (2006-2007)
  • 10 Clinical Chemistry Test Reagents In Germany
    • 10.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2015)
    • 10.2 Clinical Chemistry Test Reagents Distribution Share (2007-2008)
    • 10.3 Clinical Chemistry Test Reagents, Germany, Company Share (2006-2007)
  • 11 Genetic Test Reagents In Germany
    • 11.1 Genetic Test Reagents Overall Revenue (2000-2015)
    • 11.2 Genetic Test Reagents Distribution Share (2007-2008)
    • 11.3 Genetic Test Reagents, Germany, Company Share (2006-2007)
  • 12 Immunochemistry Test Reagents In Germany
    • 12.1 Immunochemistry Test Reagents Overall Revenue (2000-2015)
      • 12.1.1 Disease Specific Markers Revenue (2000-2015)
      • 12.1.2 Disease Specific Test Reagents Revenue (2000-2015)
      • 12.1.3 Drug Related Testing Reagents Revenue (2000-2015)
      • 12.1.4 Hormone Related Testing Reagents Revenue (2000-2015)
    • 12.2 Immunochemistry Test Reagents Distribution Share (2007-2008)
    • 12.3 Immunochemistry Test Reagents, Germany, Company Share (2006-2007)
  • 13 Infectious Immunology Test Reagents In Germany
    • 13.1 Infectious Immunology Test Reagents Overall Revenue (2000-2015)
      • 13.1.1 Virology Revenue (2000-2015)
    • 13.2 Infectious Immunology Test Reagents Distribution Share (2007-2008)
    • 13.3 Infectious Immunology Test Reagents, Germany, Company Share (2006-2007)
  • 14 Instruments In Germany
    • 14.1 Instruments Overall Revenue (2000-2015)
    • 14.2 Instruments Distribution Share (2007-2008)
  • 15 Microbiology Test Reagents In Germany
    • 15.1 Microbiology Test Reagents Overall Revenue (2000-2015)
      • 15.1.1 Bacteriology Test Reagents Revenue (2000-2015)
    • 15.2 Microbiology Test Reagents Distribution Share (2007-2008)
    • 15.3 Microbiology Test Reagents, Germany, Company Share (2006-2007)
  • 16 Self Testing In Germany
    • 16.1 Self Testing Overall Revenue (2000-2015)
    • 16.2 Self Testing Distribution Share (2007-2008)
    • 16.3 Self Testing, Germany, Company Share (2006-2007)
  • 17 Overview of Key Companies in Germany In Vitro Diagnostics Market
    • 17.1 F. Hoffmann-La Roche Ltd. Company Profile
      • 17.1.1 Company Overview
      • 17.1.2 Value Chain Analysis
        • 17.1.2.1 Manufacturing
        • 17.1.2.2 Product Development
    • 17.2 Abbott Laboratories Company Profile
      • 17.2.1 Company Overview
      • 17.2.2 Value Chain Analysis
        • 17.2.2.1 Manufacturing
        • 17.2.2.2 Product Development
        • 17.2.2.3 Sales and Marketing
    • 17.3 Dade Behring Holdings, Inc. Company Profile
      • 17.3.1 Company Overview
    • 17.4 Beckman Coulter, Inc. Company Profile
      • 17.4.1 Company Overview
      • 17.4.2 Value Chain Analysis
        • 17.4.2.1 Manufacturing
        • 17.4.2.2 Product Development
        • 17.4.2.3 Sales and Marketing
      • 17.4.3 Beckman Coulter, Inc. Pipeline Products
        • 17.4.3.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type
        • 17.4.3.2 Beckman Coulter, Inc. Pipeline Products By Development Stage
        • 17.4.3.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area
        • 17.4.3.4 Beckman Coulter, Inc. Pipeline Products By News Summary
    • 17.5 Ortho-Clinical Diagnostics Inc. Company Profile
      • 17.5.1 Company Overview
      • 17.5.2 Ortho-Clinical Diagnostics Inc. Pipeline Products
        • 17.5.2.1 Ortho-Clinical Diagnostics Inc. Pipeline Products By Equipment Type
        • 17.5.2.2 Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
        • 17.5.2.3 Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
        • 17.5.2.4 Ortho-Clinical Diagnostics Inc. Pipeline Products By News Summary
    • 17.6 bioMerieux S.A. Company Profile
      • 17.6.1 Company Overview
      • 17.6.2 Value Chain Analysis
        • 17.6.2.1 Manufacturing
        • 17.6.2.2 Product Development
        • 17.6.2.3 Sales and Marketing
    • 17.7 Siemens Healthcare Company Profile
      • 17.7.1 Company Overview
      • 17.7.2 Value Chain Analysis
        • 17.7.2.1 Manufacturing
        • 17.7.2.2 Product Development
        • 17.7.2.3 Sales and Marketing
    • 17.8 8sens.biognostic GmbH Company Profile
      • 17.8.1 Company Overview
    • 17.9 AdnaGen AG Company Profile
      • 17.9.1 Company Overview
    • 17.10 AESKU.DIAGNOSTICS Company Profile
      • 17.10.1 Company Overview
    • 17.11 BRAHMS Aktiengesellschaft Company Profile
      • 17.11.1 Company Overview
      • 17.11.2 BRAHMS Aktiengesellschaft Pipeline Products
        • 17.11.2.1 BRAHMS Aktiengesellschaft Pipeline Products By Equipment Type
        • 17.11.2.2 BRAHMS Aktiengesellschaft Pipeline Products By Development Stage
        • 17.11.2.3 BRAHMS Aktiengesellschaft Pipeline Products By Therapy Area
        • 17.11.2.4 BRAHMS Aktiengesellschaft Pipeline Products By Clinical Trials
        • 17.11.2.5 BRAHMS Aktiengesellschaft Pipeline Products By News Summary
    • 17.12 BioRepair GmbH Company Profile
      • 17.12.1 Company Overview
    • 17.13 Centronic GmbH Company Profile
      • 17.13.1 Company Overview
    • 17.14 Epigenomics AG Company Profile
      • 17.14.1 Company Overview
    • 17.15 Epigenomics AG Pipeline Products
      • 17.15.1 Epigenomics AG Pipeline Products By Equipment Type
      • 17.15.2 Epigenomics AG Pipeline Products By Development Stage
      • 17.15.3 Epigenomics AG Pipeline Products By Therapy Area
      • 17.15.4 Epigenomics AG Pipeline Products By Clinical Trials
      • 17.15.5 Epigenomics AG Pipeline Products By News Summary
    • 17.16 Hain Lifescience GmbH Company Profile
      • 17.16.1 Company Overview
    • 17.17 Invitek Biotechnolgy & Biodesign Ltd. Company Profile
      • 17.17.1 Company Overview
      • 17.17.2 Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products
        • 17.17.2.1 Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products By Equipment Type
        • 17.17.2.2 Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products By Development Stage
        • 17.17.2.3 Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products By Therapy Area
    • 17.18 Serion Immundiagnostica GmbH Company Profile
      • 17.18.1 Company Overview
    • 17.19 Viramed Biotech AG Company Profile
      • 17.19.1 Company Overview
  • 18 Financial Deals Landscape
    • 18.1 Partnerships
      • 18.1.1 Epigenomics Enters Into an Agreement with Quest Diagnostics
      • 18.1.2 Kreatech Enters Into An Agreement With BioMicro Systems
      • 18.1.3 Medizinische Hochschule Hannover Signs An Agreement With Roche Diagnostics
      • 18.1.4 Exiqon Signs An Agreement With Roche Diagnostics
  • 19 Recent Developments
    • 19.1 Strategy and Business Planning
      • 19.1.1 Oct 09, 2008: Abbott Opens New Research Facility and Pilot Plant in Ludwigshafen
      • 19.1.2 Oct 01, 2008: Roche Invests CHF215 Million In Diagnostics Facility At Penzberg, Munich
    • 19.2 Legal and Regulatory
      • 19.2.1 Jan 22, 2009: QIAGEN and Applied Biosystems Settle All Disputes Over Real-Time PCR Thermal Cycler Patents
    • 19.3 Product News
      • 19.3.1 Feb 25, 2009: BRAHMS Submits MR-proANP Kryptor For FDA Approval
      • 19.3.2 Oct 16, 2008: Primo Star iLEDFaster Detection Of Tuberculosis Using A New Microscope From Carl Zeiss
      • 19.3.3 Oct 16, 2008: SIRS-Lab Receives ISO Certification For VYOO, Molecular In-Vitro Sepsis Diagnostics
  • 20 Appendix
    • 20.1 Global Markets Direct Research Methodology
    • 20.2 Coverage
    • 20.3 Secondary Research
    • 20.4 Primary Research
    • 20.5 Models
    • 20.6 Forecasts
    • 20.7 Expert Panel Validation
    • 20.8 Currency Conversion
    • 20.9 Contact Us
    • 20.10 Disclaimer
  • 1 List of Tables
    • Table 1: Healthcare Expenditure in Germany, (m), 2000 2006
    • Table 2: Healthcare Personnel by Region in Germany, 2007
    • Table 3: Doctors by Specialty in Germany, 2000-2004
    • Table 4: Hospitals by Region in Germany, 2004
    • Table 5: Hospitals and Beds by Region in Germany, 2007
    • Table 6: Rehabilitation Centers by Region in Germany, 2004
    • Table 7: Rehabilitation Center Beds by Region in Germany, 2004
    • Table 8: Discharges by Diagnosis in Germany, 2004
    • Table 9: In Vitro Diagnostics, Germany, Overall Revenue ($ mn), 2000-2015
    • Table 10: In Vitro Diagnostics, Germany, Cross-Category Analysis, 2000-2015
    • Table 11: In Vitro Diagnostics, Germany, Overall Revenue ($ mn), Historic, 2000-2008
    • Table 12: In Vitro Diagnostics, Germany, Overall Revenue ($ mn), Forecast, 2008-2015
    • Table 13: In Vitro Diagnostics, Germany, Company Share by Revenue ($ mn), 2006-2007
    • Table 14: Blood Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 15: Blood Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 16: Haematology Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 17: Haematology Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 18: Hemostasis Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 19: Hemostasis Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 20: Blood Test Reagents, Germany, Distribution Share by Revenue ($mn), 2007-2008
    • Table 21: Blood Test Reagents, Germany, Company Share by Revenue ($ mn), 2006-2007
    • Table 22: Clinical Chemistry Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 23: Clinical Chemistry Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 24: Clinical Chemistry Test Reagents, Germany, Distribution Share by Revenue ($mn), 2007-2008
    • Table 25: Clinical Chemistry Test Reagents, Germany, Company Share by Revenue ($ mn), 2006-2007
    • Table 26: Genetic Test Reagents, Germany, Revenue ($ mn), Historic, 2000-2008
    • Table 27: Genetic Test Reagents, Germany, Revenue ($ mn), Forecast, 2008-2015
    • Table 28: Genetic Test Reagents, Germany, Distribution Share by Revenue ($mn), 2007-2008
    • Table 29: Genetic Test Reagents, Germany, Company Share by Revenue ($ mn), 2006-2007
    • Table 30: Immunochemistry Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 31: Immunochemistry Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 32: Disease Specific Markers, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 33: Disease Specific Markers, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 34: Disease Specific Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 35: Disease Specific Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 36: Drug Related Testing Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 37: Drug Related Testing Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 38: Hormone Related Testing Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 39: Hormone Related Testing Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 40: Immunochemistry Test Reagents, Germany, Distribution Share by Revenue ($mn), 2007-2008
    • Table 41: Immunochemistry Test Reagents, Germany, Company Share by Revenue ($ mn), 2006-2007
    • Table 42: Infectious Immunology Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 43: Infectious Immunology Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 44: Virology, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 45: Virology, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 46: Infectious Immunology Test Reagents, Germany, Distribution Share by Revenue ($mn), 2007-2008
    • Table 47: Infectious Immunology Test Reagents, Germany, Company Share by Revenue ($ mn), 2006-2007
    • Table 48: Instruments, Germany, Revenue ($ mn), Historic, 2000-2008
    • Table 49: Instruments, Germany, Revenue ($ mn), Forecast, 2008-2015
    • Table 50: Instruments, Germany, Distribution Share by Revenue ($mn), 2007-2008
    • Table 51: Microbiology Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 52: Microbiology Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 53: Bacteriology Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 54: Bacteriology Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 55: Microbiology Test Reagents, Germany, Distribution Share by Revenue ($mn), 2007-2008
    • Table 56: Microbiology Test Reagents, Germany, Company Share by Revenue ($ mn), 2006-2007
    • Table 57: Self Testing, Germany, Revenue ($ mn), Historic, 2000-2008
    • Table 58: Self Testing, Germany, Revenue ($ mn), Forecast, 2008-2015
    • Table 59: Self Testing, Germany, Distribution Share by Revenue ($mn), 2007-2008
    • Table 60: Self Testing, Germany, Company Share by Revenue ($ mn), 2006-2007
    • Table 61: Beckman Coulter, Inc. Pipeline Products by Equipment Type
    • Table 62: Beckman Coulter, Inc. Pipeline Products By Development Stage
    • Table 63: Beckman Coulter, Inc. Pipeline Products By Therapy Area
    • Table 64: Beckman Coulter, Inc. Pipeline Products By News Summary
    • Table 65: Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type
    • Table 66: Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
    • Table 67: Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
    • Table 68: Ortho-Clinical Diagnostics Inc. Pipeline Products By News Summary
    • Table 69: BRAHMS Aktiengesellschaft Pipeline Products by Equipment Type
    • Table 70: BRAHMS Aktiengesellschaft Pipeline Products By Development Stage
    • Table 71: BRAHMS Aktiengesellschaft Pipeline Products By Therapy Area
    • Table 72: BRAHMS Aktiengesellschaft Pipeline Products By Clinical Trials
    • Table 73: BRAHMS Aktiengesellschaft Pipeline Products By News Summary
    • Table 74: Epigenomics AG Pipeline Products by Equipment Type
    • Table 75: Epigenomics AG Pipeline Products By Development Stage
    • Table 76: Epigenomics AG Pipeline Products By Therapy Area
    • Table 77: Epigenomics AG Pipeline Products By Clinical Trials
    • Table 78: Epigenomics AG Pipeline Products By News Summary
    • Table 79: Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products by Equipment Type
    • Table 80: Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products By Development Stage
    • Table 81: Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products By Therapy Area
    • Table 82: Epigenomics Enters Into An Agreement With Quest Diagnostics
    • Table 83: Kreatech Enters Into An Agreement With BioMicro Systems
    • Table 84: Medizinische Hochschule Hannover Signs An Agreement With Roche Diagnostics
    • Table 85: Exiqon Signs An Agreement With Roche Diagnostics
    • Table 86: USD to Local Currency, Average Exchange Rate 2008
  • 1.2 List of Figures
    • Figure 1: Healthcare Expenditure Sources in Germany, 2006
    • Figure 2: Healthcare Financing Framework in Germany, 2007
    • Figure 3: Flowchart for Classification of Non-invasive Devices in Germany, 2007
    • Figure 4: Flowchart for Classification of Invasive Devices in Germany, 2007
    • Figure 5: Flowchart for Classification of Invasive Devices in Germany, 2007
    • Figure 6: Classification of Invasive Devices in Germany, 2007
    • Figure 7: Classification of Invasive Devices in Germany, 2007
    • Figure 8: Flowchart for Classification of Active Devices in Germany, 2007
    • Figure 9: Flowchart for Classification of Active Devices in Germany, 2007
    • Figure 10: Flowchart for Classification of Devices except Non-invasive, Invasive and Active Devices in Germany, 2007
    • Figure 11: Conformity Assessment of Class-I Medical Devices in Germany, 2007
    • Figure 12: Conformity Assessment of Class-IIa Medical Devices in Germany, 2007
    • Figure 13: Conformity Assessment of Class-IIb Medical Devices in Germany, 2007
    • Figure 14: Conformity Assessment of Class-III Medical Devices in Germany, 2007
    • Figure 15: In Vitro Diagnostics, Germany, Overall Revenue ($ mn), 2000-2015
    • Figure 16: In Vitro Diagnostics, Germany, Cross-Category Analysis, 2000-2015
    • Figure 17: In Vitro Diagnostics, Germany, Overall Revenue ($ mn), Historic, 2000-2008
    • Figure 18: In Vitro Diagnostics, Germany, Overall Revenue ($ mn), Forecast, 2008-2015
    • Figure 19: In Vitro Diagnostics, Germany, Company Share (%), 2007
    • Figure 20: Blood Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 21: Blood Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 22: Haematology Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 23: Haematology Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 24: Hemostasis Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 25: Hemostasis Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 26: Blood Test Reagents, Germany, Company Share (%), 2007
    • Figure 27: Clinical Chemistry Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 28: Clinical Chemistry Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 29: Clinical Chemistry Test Reagents, Germany, Company Share (%), 2007
    • Figure 30: Genetic Test Reagents, Germany, Revenue ($ mn), Historic, 2000-2008
    • Figure 31: Genetic Test Reagents, Germany, Revenue ($ mn), Forecast, 2008-2015
    • Figure 32: Genetic Test Reagents, Germany, Company Share (%), 2007
    • Figure 33: Immunochemistry Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 34: Immunochemistry Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 35: Disease Specific Markers, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 36: Disease Specific Markers, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 37: Disease Specific Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 38: Disease Specific Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 39: Drug Related Testing Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 40: Drug Related Testing Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 41: Hormone Related Testing Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 42: Hormone Related Testing Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 43: Immunochemistry Test Reagents, Germany, Company Share (%), 2007
    • Figure 44: Infectious Immunology Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 45: Infectious Immunology Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 46: Virology, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 47: Virology, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 48: Infectious Immunology Test Reagents, Germany, Company Share (%), 2007
    • Figure 49: Instruments, Germany, Revenue ($ mn), Historic, 2000-2008
    • Figure 50: Instruments, Germany, Revenue ($ mn), Forecast, 2008-2015
    • Figure 51: Microbiology Test Reagents, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 52: Microbiology Test Reagents, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 53: Bacteriology Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 54: Bacteriology Test Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 55: Microbiology Test Reagents, Germany, Company Share (%), 2007
    • Figure 56: Self Testing, Germany, Revenue ($ mn), Historic, 2000-2008
    • Figure 57: Self Testing, Germany, Revenue ($ mn), Forecast, 2008-2015
    • Figure 58: Self Testing, Germany, Company Share (%), 2007
    • Figure 59: F. Hoffmann-La Roche Ltd Value Chain Analysis
    • Figure 60: Abbott Laboratories Value Chain Analysis
    • Figure 61: Beckman Coulter, Inc. Value Chain Analysis
    • Figure 62: Biomerieux Sa Value Chain Analysis
    • Figure 63: Siemens Medical Solutions Value Chain Analysis
    • Figure 64: Global Markets Direct Methodology